Last reviewed · How we verify

NCT03876509

Non-invasive Diagnosis of Pulmonary Hypertension by Impedance Cardiography

Completed Last updated 18 November 2020
What this trial tests

trial testing Impedance Cardiography in Pulmonary Hypertension in 86 participants. Completed in 30 June 2020.

Timeline
4 July 2018
Primary endpoint
30 June 2020
30 June 2020

Quick facts

Lead sponsorMedical University of Graz
StatusCompleted
Study typeOBSERVATIONAL
Enrollment86
Start date4 July 2018
Primary completion30 June 2020
Estimated completion30 June 2020
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Graz

Who can join

Adults 18 to 99, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the study is to prospectively evaluate Impedance Cardiography as a tool to detect pulmonary hypertension. According to our hypothesis Impedance Cardiography is a valuable method to differentiate patients without pulmonary hypertension from patients with pulmonary hypertension. The main objective is to determine the sensitivity and specificity in comparison to the gold standard right heart catheterization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Impedance Cardiography

Trials testing the same drug.

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03876509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing